

ADVERTISING SUPPLEMENT

**Service area:****Year established****Top local executives****TO VOLUNTEER**

please visit:

www.abc2.org/join-us/volunteer

2015-16 FUNDRAISING

There are many ways to get involved with ABC². For more information, please visit:

www.abc2.org/join-us/events

Upcoming events include:

- 6th Annual Florida Brain Cancer 5K – March 6, 2016 – Lake Worth, FL
- 19th Annual Race for Hope 5K – May 1, 2016 – Washington, D.C.
- 4th Annual Over The Edge for Brain Cancer – Fall 2016 – San Diego, CA

FROM OUR FRIENDS

“ABC² is focused on driving innovation, focused on driving collaboration, focused on more entrepreneurship in this field.”

— **Steve Case**, Co-Founder and Chair of ABC² Board of Directors; Chairman and CEO of Revolution LLC

“Accelerate Brain Cancer Cure - they lead the field. They're doing things that without their presence couldn't have been done and without their continued support will not be done.”

— **Dr. Henry S. Friedman**, world-renowned neuro-oncologist and Deputy Director at The Preston Robert Tisch Brain Tumor Center at Duke

ABC² (Accelerate Brain Cancer Cure)

ABC² pursues a single straightforward goal: to advance breakthrough treatments for patients with brain cancer.

OUR HISTORY

In 2001, Dan Case was diagnosed with brain cancer. Disappointed by the lack of information and limited treatment options, Dan, together with his wife, Stacey, his brother, Steve, and Steve's wife, Jean, co-founded ABC². Dan died from his cancer the following year, but with his help ABC² had already begun to develop its unique business model of bringing together industry, academia, government and non-profit venture finance to accelerate the ways in which new therapies are brought to patients.

- We have made more than 100 grants totaling over \$20 Million to world-renowned researchers and physicians from 54 institutions.
- We invest in high risk, high reward research.

- We provide seed funding for pharma and biotech companies to focus on brain cancer. An early ABC² collaboration with Genentech led to the May, 2009, approval of Avastin for use in treating recurrent GBM -- the first new brain tumor treatment approved in over a decade.

- We bring the power of genomic diagnostics and tumor profiling to patients.

- We've funded six promising immunotherapies.

- We don't just fund research, we focus on advancing treatments and have brought more than a dozen new treatments into the clinic.

**WAYS TO GIVE**

One of the most straightforward ways that you can help our cutting-edge scientific ventures is by donating. Your dollars will advance breakthrough research projects desperately in need of funding. You can support ABC² through:

- General donations
- Memorial and tribute donations
- Gifts of stock, securities and mutual funds
- Planned giving
- Special event participation
- Sponsorship and underwriting

For major gifts, please call 202-419-3140.

Donate online at www.abc2.org/donate
By check via mail:

ABC² (Accelerate Brain Cancer Cure)
1717 Rhode Island Avenue, N.W.
Suite 700
Washington, DC 20036

GOALS

- **Our Unconventional Approach** - Brain cancer breakthroughs don't follow conventional wisdom. Neither do we. ABC² partners with scientists, physicians and companies to push the limits of science and technology.

- **Our Enterprising Attitude** - As venture philanthropists, we “buy down the risk” for researchers to collaborate with the companies that can develop new patient treatments. Our fast-track awards process quickly fills gaps in the R&D pipeline and rapidly catalyzes novel research advancements. Our proven business know-how helps leverage funding that may not have been previously invested in brain cancer research.

- **Our Collaborative Style** - ABC² was built on the idea that we will be more effective in our work if we build the right teams to address the complex challenges that exist in this most difficult field. We make collaborations happen.

GIVING

With your support of our venture philanthropy approach, we can drive the development of drugs that might not otherwise move forward. We don't view ourselves as just investors, we are value-added partners who not only provide capital but also deep domain expertise and contacts. For example, ABC² created our Allele project to bring robust advanced genomic profiling to brain cancer patients.

Allele is a collaboration with The Broad Institute and cancer centers such as Dana Farber Cancer Institute that brings together the best in cancer research with the best in cancer treatment. Allele generates, at no cost to patients, advanced clinical diagnostic reports for brain cancer patients by doing robust

whole exome sequencing of both their tumor and normal tissue.

By aggregating a large amount of sequencing data, Allele enables us to understand how tumors evolve over time and why they develop resistance to traditional cancer therapies. Allele provides the missing framework to advance novel targeted and immunotherapies and takes away risk for those developing the next generation of brain cancer therapies. By providing real time data, the Allele platform enables clinicians to better understand which treatments will best work for which patients.

Allele empowers patients to make more informed decisions and researchers to bring forward the most promising new therapies.

FOR THOSE WHO DARE

“ABC² is BOLD. They act with urgency and embrace risk in order to speed new treatments for patients like me”

— BethAnn Telford,
extreme athlete and
10-year brain cancer survivor

ABC²
Brain Cancer Breakthroughs

www.abc2.org